All LABAs are associated with an increased risk of asthma-related deaths. Indacaterol is indicated for patients with COPD and not for patients with asthma. Indacaterol should not be used for ...

Review the side-effects of Indacaterol as documented in medical literature. The term "side effects" refers to unintended effects that can occur as a result of taking the medication. In majority of ...

QVM149 is a triple therapy consisting of indacaterol (acetate), glycopyrronium (bromide) and mometasone (furoate), which is being developed as a daily inhaled treatment for asthma delivered via ...

Enerzair (formerly QVM149) consists of long-acting beta agonist (LABA) indacaterol, long-acting muscarinic antagonist (LAMA) glycopyrronium, and inhaled corticosteroid (ICS) mometasone furoate ...